Reported 8 months ago
Zhenwei Biotechnology, founded by a group of Ph.D. graduates from the biotechnology industry of National Cheng Kung University, has made significant progress in analyzing the 'inflammatory response' in the laboratory over the years. Since winning the first prize of the Innovative Entrepreneurship Incentive Program (FITI) in 2018, they have developed a variety of antibody drugs, peptide drugs, and diagnostic reagents for tracking disease progression targeting key proteins for the treatment of chronic diseases. The company also extends their technology to the skincare line 'Zhenqi Skin'. By targeting common inflammatory response factors activated by various stimuli, Zhenwei Biotechnology has developed peptide inhibitors aiming to simplify and directly address chronic inflammatory diseases caused by abnormal inflammatory responses. The company is dedicated to developing drugs not only for human chronic inflammatory diseases but also exploring the application of peptide products in various fields. Zhenwei Biotechnology is also striving to expand into the skincare, medical diagnostics, pet medical drugs, and health food markets to support their key protein antibody drug in auxiliary cancer treatment and clinical trials for conditions such as pulmonary fibrosis post-pandemic. The general manager, Du Junyi, expressed the company's hope to achieve the goal of 'broad-spectrum drugs' through their antibody drugs in the near future, after completing preclinical animal testing in the current drug development process.
Source: YAHOO